The company working to build a cancer drug with AI is opening a lab in Israel

The U.S. startup company DeepCure, which works to develop medications with the help of artificial intelligence, said this week that it will be opening a lab and offices in Israel for the first time. DeepCure is part of an emerging wave of companies seeking to improve and accelerate the drug-development process with tools like machine learning and AI. It was formed in 2018 by CEO Kfir Schreiber, alongside Joseph Jacobson and Thrasyvoulos (Thras) Karydis, who are today chief science and chief technology officer, respectively. The three met as students at the Massachusetts Institute of Technology. The company is developing small molecules drugs– in other words, medicines generally sold in capsule form, as opposed to antibody-based biological therapies given as an infusion, for example. DeepCure currently has five development programs underway for therapies against cancer, inflammatory diseases and nervous system diseases.